Rubix Group
Rubix Group (HK) Limited is a Hong Kong-based private single family office that deploys proprietary family capital into Greater China healthcare and life sciences opportunities across biotech, medical devices, digital health, and healthcare services verticals, serving exclusively its controlling family group.
- Company typePrivate
- Founded2020
- HeadquartersHong Kong, Hong Kong SAR China
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Rubix Group does
Rubix Group (HK) Limited is a Hong Kong-incorporated private single family office, established in 2020, that deploys proprietary family capital into healthcare and life sciences opportunities across Greater China. The firm serves exclusively the members of its controlling family and family-owned investment holding vehicles; it does not solicit, accept, or manage capital from third parties and does not charge management or performance fees. Its sole 'customer' is the family itself, and its revenue, in the economic sense, is derived from investment gains on the family's own portfolio rather than from fee income.
The firm invests across four healthcare verticals in Greater China: Biotech & Therapeutics (novel biologics, small molecules, cell and gene therapy, oncology, immunology, CNS, rare disease, biosimilars); Medical Devices & MedTech (surgical robotics, diagnostic imaging, interventional devices, orthopaedics, IVD, wearables); Healthcare Services & Infrastructure (CRO/CDMO, hospital groups, specialty clinics, pharmacy chains, healthcare IT, laboratory services); and Digital Health & AI (AI drug discovery, telemedicine, clinical decision support, genomics, precision medicine) as an emerging focus. Its core capabilities cover deal origination through local biotech networks, independent commercial and scientific due diligence, bespoke transaction structuring (direct equity, convertibles, structured notes, SPVs), active position stewardship with board representation, risk governance, and exit planning across HKEX, Shanghai, and Shenzhen exchanges.
There is no proprietary technology platform; the firm's edge is grounded in on-the-ground presence in Hong Kong, local-language diligence, and relationships with Greater China healthcare management teams. Operating infrastructure is distributed across Hong Kong (principal entity), Cayman Islands (Rubix Capital SPC), British Virgin Islands (Rubix Capital (BVI) Ltd, an Approved Manager), and Malaysia (operations centre), while investment decision-making remains independent at Rubix Group (HK) Limited, which is not licensed by the Securities and Futures Commission of Hong Kong. The family principal, Alexander Ariana, serves as CEO and oversees the principal investing programme.
Rubix Group firmographics
Firmographics- Name
- Rubix Group
- Legal name
- Rubix Group (HK) Limited
- Website
- https://rubixgp.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Rubix Group (HK) Limited is a Hong Kong-based private single family office that deploys proprietary family capital into Greater China healthcare and life sciences opportunities across biotech, medical devices, digital health, and healthcare services verticals, serving exclusively its controlling family group.
- Ownership category
- akta.pro rank
Rubix Group industry classification
Industry- Product category
- Family Office Healthcare Investment
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investors, Nec (6799)
- akta.pro primary industry
- Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest) (FSAAADAH)
Keywords
Where Rubix Group is headquartered
LocationHeadquarters
- HQ city
- Hong Kong
- HQ country
- Hong Kong SAR China
- HQ region
- Asia
Offices4 records
Markets served
Rubix Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Investment Returns on Proprietary Family Capital: Rubix Group generates returns through investment gains on the family's proprietary capital deployed across Greater China healthcare and life sciences opportunities. As a single family office, it does not charge management fees or performance fees to external clients. Revenue is derived entirely from appreciation and returns on the family's own investment portfolio.
Go-to-market motion1 record
Rubix Group product offering
Product offeringCore offering
Rubix Group is a Hong Kong-incorporated private single family office that deploys its controlling family's proprietary capital directly into Greater China healthcare and life sciences companies. The firm concentrates on four verticals — biotech and therapeutics, medical devices and MedTech, digital health and AI, and healthcare services and infrastructure — sourcing proprietary deal flow through local networks and managing direct equity, convertible, and structured positions as principal investor.
Product overview
Rubix Group is a private single family office providing principal investing services in Greater China healthcare and life sciences. The firm offers a single unified service focused on deploying proprietary family capital across four investment verticals: Biotech & Therapeutics, Medical Devices & MedTech, Digital Health & AI, and Healthcare Services & Infrastructure. The core service includes deal origination, due diligence, transaction structuring, position stewardship, risk governance, and exit planning capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Principal Investing Services
- Biotech & Therapeutics Investment
- Medical Devices & MedTech Investment
- Digital Health & AI Investment
- Healthcare Services & Infrastructure Investment
Companies that use Rubix Group
Customer profileSegments1 record
Ideal customer profiles1 record
Rubix Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Rubix Group partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Rubix Group competitors and assessment
Company assessmentDirect peers
- Loyal Valley Capital: Chinese private equity firm with material healthcare and life sciences investment activity alongside other verticals. Comparable as a Greater China-focused principal investor with concentrated healthcare deal flow, though broader in sector mandate.
- OrbiMed: Global healthcare-dedicated investment firm covering biotech, medical devices, and healthcare services across stages and geographies. Comparable as a sector-focused specialist investor with concentrated, conviction-driven healthcare exposure, though broader geographically.
- Vivo Capital: Healthcare-focused investment firm with established Greater China presence investing across biotech, medical devices, and healthcare services. Comparable as a sector-specialist investor with concentrated conviction-driven approach to healthcare.
- Highlight Capital: Healthcare-focused private equity firm with significant Greater China presence, investing across biotech, medical devices, and healthcare services. Comparable as a sector-specialist investor with concentrated healthcare focus across the same regional opportunity set.
- Lake Bleu Capital: Hong Kong-based healthcare-focused investment manager specializing in Greater China healthcare equities across biotech, medical devices, and healthcare services. Directly comparable as a healthcare-vertical specialist investor focused on the same regional opportunity set.
- Qiming Venture Partners: China-focused venture capital firm with one of the strongest healthcare and biotech portfolios in Greater China, investing across biotech, medical devices, and digital health. Comparable as a sector-active investor with concentrated healthcare exposure in the same geography.
Regional players
- CDB Capital: China Development Bank's investment arm with significant healthcare and life sciences activity across Mainland China. Comparable as a Greater China healthcare investor, though institutionally distinct in origin, scale, and mandate.
Broad incumbents
- CDH Investments: Established Greater China private equity firm with healthcare and life sciences investment activity. Comparable as a large-scale China-focused principal investor with cross-jurisdictional deal capabilities.
- Boyu Capital: Major Greater China-focused private equity firm with healthcare exposure among its broad sector coverage. Comparable as a large-scale principal investor in Greater China, though much broader in sector mandate and substantially larger in AUM.
- Hillhouse Capital: One of the largest Asia-focused investment firms with significant healthcare and life sciences exposure across Greater China. Comparable as a major Greater China investor with healthcare vertical presence, though much broader in mandate and substantially larger in scale.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Rubix Group social profiles
Digital presenceRubix Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rubix Group leadership team
Management profileNumber of profiles
Profiles1 record
Rubix Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rubix Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rubix Group
What does Rubix Group do?
Rubix Group is a Hong Kong-incorporated private single family office that deploys its controlling family's proprietary capital directly into Greater China healthcare and life sciences companies. The firm concentrates on four verticals — biotech and therapeutics, medical devices and MedTech, digital health and AI, and healthcare services and infrastructure — sourcing proprietary deal flow through local networks and managing direct equity, convertible, and structured positions as principal investor.
Is Rubix Group a public or private company?
Rubix Group is a private company. It is classified as family owned and is currently operating.
When was Rubix Group founded?
Rubix Group was founded in 2020. It employs 1 to 10 people.
Where is Rubix Group based?
Rubix Group is headquartered in Hong Kong, Hong Kong SAR China, in the Asia region.
How does Rubix Group make money?
One revenue line is on record: investment Returns on Proprietary Family Capital.
Who are Rubix Group's main competitors?
Direct peers on record are Loyal Valley Capital, OrbiMed, Vivo Capital, Highlight Capital, Lake Bleu Capital and Qiming Venture Partners. CDB Capital is listed as a regional player. Broad incumbents are CDH Investments, Boyu Capital and Hillhouse Capital.
Does Rubix Group have an API?
No public API is recorded for Rubix Group.
What industry is Rubix Group in?
Rubix Group's product category is Family Office Healthcare Investment. Its primary akta.pro industry code is FSAAADAH, Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest). Its NAICS code is 523940 and its SIC code is 6799.